Dermapharm Holding

Dermapharm reports a revenue increase of around 5% in H1 2026 and adjusted EBITDA growth of about 14%, lifting the EBITDA margin by 2 percentage points. Stronger branded drug sales and an improved cash conversion of 65% offset a EUR 30m write-down on a receivable from the Dutch cannabis business. Operating cash flow rose by EUR 35m, free-cash-flow yield stands at 12%; management confirmed the full-year forecast but does not expect to exceed it. The share price rose moderately, while higher leverage after share buybacks and an ongoing BaFin review were cited as risks. » Mais em de.investing.com

Dermapharm reports momentum in the second quarter driven by branded medicines and the acquisitions of Mucos and F. Trenka. Revenue rose in the first half by 2.9% to €591.0 million, adjusted EBITDA climbed to €163.2 million and the margin to 27.6%. The group confirms its 2026 guidance (revenue €1.182–1.218 billion; adjusted operating profit €331–341 million). Analysts reacted positively, while BaFin is conducting a review of the 2025 financial statements. » Mais em finanzen.net

Dermapharm reported first-half sales up 2.9% to €591.0m and an adjusted EBITDA of €163.2m, with the margin rising to 27.6%. Drivers were organic growth in branded medicines and the acquisitions of Mucos and F. Trenka, while Arkopharma performed more weakly. The company confirms its 2026 full-year guidance of €1.182–1.218bn in sales and an adjusted operating result of €331–341m. BaFin has meanwhile opened reviews of the 2025 annual financial statements. » Mais em finanzen.net